The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Leflunomide: A Review of its Use in Active Rheumatoid Arthritis
Abstract
Unlabelled A77 1726, the active metabolite of leflunomide, is an immunomodulator which inhibits cell proliferation in activated lymphocytes in patients with active rheumatoid arthritis. Because A77 1726 has a long half-life (approximately 2 weeks), treatment with oral leflunomide is initiated with a loading dose of 100mg once daily for 3 days and continued with 20mg once daily. Results of large randomised, double-blind, multicentre trials of up to 24 months' duration have shown that leflunomide is significantly superior to placebo and at least as effective as sulfasalazine in improving primary outcome measures, such as tender joint counts, swollen joint counts and physicians' and patients' global assessment, in adult patients with active rheumatoid arthritis. Whereas improvement in all primary outcome measures with leflunomide was similar to or significantly less than that with methotrexate after 12 months, the efficacy of both agents was similar after 24 months. The therapeutic effect of leflunomide appears earlier (at 4 weeks) than that of sulfasalazine or methotrexate, and reduction from baseline values in functional disability was significantly greater with leflunomide than with sulfasalazine, methotrexate or placebo at end-point. Leflunomide was at least as effective as sulfasalazine or methotrexate in delaying the rate of radiological progression of disease. The most common adverse events reported in patients receiving leflunomide in randomised double-blind, placebo-controlled trials were diarrhoea (27%), respiratory infections (21%), nausea (13%), headache (13%), rash (12%), increased serum hepatic aminotransferases (10%), dyspepsia (10%) and alopecia (9%). Leflunomide was as well tolerated as sulfasalazine or methotrexate in clinical trials. Monitoring of serum hepatic enzyme levels is recommended in patients receiving leflunomide. The drug is not recommended in female patients who are or may become pregnant. Drug treatment should be discontinued, and hastened drug elimination procedure should be considered, in male patients wishing to father a child. 16 potential cases of pancytopenia and 9 cases of serious skin reactions have been associated with the use of leflunomide in 76,000 patients to date. Conclusions Leflunomide is a disease-modifying antirheumatic drug which reduces the signs and symptoms of inflammatory arthritis and delays the radiological progression of disease in adult patients with active rheumatoid arthritis. The drug appears to be as effective and as well tolerated as sulfasalazine or methotrexate, and represents a suitable alternative to these agents in adult patients with active rheumatoid arthritis. Benefits with leflunomide are evident within 4 weeks and efficacy is maintained for durations of up to 24 months.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mechanistically, the metabolic effects of leflunomide stem from its active metabolite, A77 1726, which inhibits the mitochondrial enzyme dihydroorotate dehydrogenase (DHODH).”
From Drug repurposing for cancer therapy (2024) · cites this paper as [102]
Citations
Cites
Arnett, F. C., Edworthy, S. M., Bloch, D. A., McShane, D. J., Fries, J. F., Cooper, N. S., Healey, L. A., Kaplan, S. R., Liang, M. H., Luthra, H. S., et al. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310302 · Cited by 19,753
Measurement of patient outcome in arthritis
Fries, J. F., Spitz, P. W., Kraines, R. G., & Holman, H. R. (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230202 · Cited by 4,404
American college of rheumatology preliminary definition of improvement in rheumatoid arthritis
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Fürst, D. E., Goldsmith, C. H., Katz, L. M. G., Lightfoot, R. W., Paulus, H. E., Strand, V., et al. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380602 · Cited by 2,825
Weinblatt, M. E., Kremer, J. M., Bankhurst, A. D., Bulpitt, K. J., Fleischmann, R., Fox, R. I., Jackson, C. G., Lange, M., & Burge, D. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901283400401 · Cited by 2,080
Möttönen, T. T., Hannonen, P., Leirisalo‐Repo, M., Nissilä, M., Kautiainen, H., Korpela, M. M., Laasonen, L., Julkunen, H. A., Luukkainen, R., Vuori, K., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)08513-4 · Cited by 865
Smolen, J. S., Kalden, J. R., Scott, D. L., Rozman, B., Kvien, T. K., Larsen, A., Loew-Friedrich, I., Oed, C., & Rosenburg, R. (1999) · The Lancet · doi:10.1016/s0140-6736(98)09403-3 · Cited by 771
Treatment of Active Rheumatoid Arthritis With Leflunomide Compared With Placebo and Methotrexate
Strand, V. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.21.2542 · Cited by 755
McQueen, F. M., Stewart, N. R., Crabbe, J. P., Robinson, E. T., Yeoman, S., Tan, P., & McLean, L. (1998) · Annals of the Rheumatic Diseases · doi:10.1136/ard.57.6.350 · Cited by 507
Mechanism of Action for Leflunomide in Rheumatoid Arthritis
Fox, R. I., Herrmann, M. L., Frangou, C. G., Wahl, G. M., Morris, R. E., Strand, V., & Kirschbaum, B. J. (1999) · Clinical Immunology · doi:10.1006/clim.1999.4777 · Cited by 425
van der Heijden, I. M., Wilbrink, B., Tchetverikov, I., Schrijver, I. A., Schouls, L. M., Hazenberg, M. P., Breedveld, F. C., & Tak, P. P. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200003)43:3 · Cited by 375
Cited by
Sorted by citations
Guidelines of care for the management of psoriasis and psoriatic arthritis
Gottlieb, A. B., Korman, N. J., Gordon, K. B., Feldman, S. R., Lebwohl, M., Koo, J. Y. M., Voorhees, A. S. V., Elmets, C. A., Leonardi, C. L., Beutner, K. R., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.02.040 · Cited by 766
Guidelines of care for the management of psoriasis and psoriatic arthritis
Menter, A., Korman, N. J., Elmets, C. A., Feldman, S. R., Gelfand, J. M., Gordon, K. B., Gottlieb, A. B., Koo, J. Y. M., Lebwohl, M., Lim, H. W., et al. (2009) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.03.027 · Cited by 555
Biotransformation Reactions of Five-Membered Aromatic Heterocyclic Rings
Dalvie, D., Kalgutkar, A. S. S., Khojasteh-Bakht, S. C., Obach, R. S., & O’Donnell, J. P. (2002) · Chemical Research in Toxicology · doi:10.1021/tx015574b · Cited by 523
Drug repurposing for cancer therapy
Xia, Y., Sun, M., Huang, H., & Jin, W.-L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01808-1 · Cited by 443
Next generation organofluorine containing blockbuster drugs
Han, J., Remete, A. M., Dobson, L. S., Kiss, L., Izawa, K., Moriwaki, H., Soloshonok, V. A., & O’Hagan, D. (2020) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2020.109639 · Cited by 316
Metadata
- Authors
- Prakash, A., & Jarvis, B.
- Corresponding author
- Prakash, Amitabh
- Venue
- Drugs
- Published
- 1999
- Volume
- 58
- Issue
- 6
- Pages
- 1137-1164
- ISSN
- 0012-6667 (ISSN-L)
- OpenAlex
- W2020790398
- Cited by
- 135
- References
- 67
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 6 · 2023: 6 · 2022: 6 · 2021: 7 · 2020: 4 · 2019: 3 · 2018: 3 · 2017: 3 · 2016: 1 · 2014: 4 · 2013: 5 · 2012: 6
- FWCI
- 2.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Keywords
- leflunomide, rheumatoid arthritis, immunomodulation, sulfasalazine, methotrexate, disease-modifying antirheumatic drugs, drug safety, adverse events, hepatotoxicity, drug interactions, pregnancy contraindication, pancytopenia, skin reactions, radiographic progression, functional disability
- MeSH terms
- Leflunomide, Adult, Animals, Anti-Inflammatory Agents, Non-Steroidal, Arthritis, Rheumatoid, Female, Humans, Isoxazoles, Male, Pregnancy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
